| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Raymond S Douglas | Q51353730 |
| P2093 | author name string | Shivani Gupta | |
| P2860 | cites work | Quality of life and occupational disability in endocrine orbitopathy | Q24652695 |
| Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease | Q28201947 | ||
| Selenium and the course of mild Graves' orbitopathy | Q28238021 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Increased generation of fibrocytes in thyroid-associated ophthalmopathy | Q33586738 | ||
| Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy | Q33624477 | ||
| The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota | Q34164149 | ||
| Genetic susceptibility to autoimmune thyroid disease: past, present, and future | Q34171280 | ||
| Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes | Q34428346 | ||
| Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy | Q34599722 | ||
| Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells | Q34613306 | ||
| CTLA4 mediates antigen-specific apoptosis of human T cells | Q34735857 | ||
| Blocking interleukin-1 in rheumatic diseases | Q34822708 | ||
| Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer | Q34994132 | ||
| B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications | Q35172012 | ||
| The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. | Q35605719 | ||
| Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. | Q35606170 | ||
| IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor | Q36944397 | ||
| Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy | Q37017200 | ||
| Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis | Q37038023 | ||
| Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy | Q37247091 | ||
| Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. | Q37363607 | ||
| Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. | Q37417167 | ||
| Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today. | Q37751767 | ||
| Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. | Q37775693 | ||
| The value of blocking IL-6 outside of rheumatoid arthritis: current perspective | Q37856141 | ||
| Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy | Q39784114 | ||
| Systemic adverse events following rituximab therapy in patients with Graves' disease. | Q40340279 | ||
| Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus | Q40581531 | ||
| Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. | Q43042591 | ||
| Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy | Q43853007 | ||
| Long-term effects of Graves' ophthalmopathy on health-related quality of life | Q44011939 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway | Q46107628 | ||
| Rituximab for thyroid eye disease | Q46542384 | ||
| CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. | Q48923891 | ||
| CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis. | Q51143830 | ||
| Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy. | Q51916133 | ||
| Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy. | Q54281231 | ||
| Infliximab: A Novel Treatment for Sight-Threatening Thyroid Associated Ophthalmopathy | Q60207430 | ||
| Humoral immunity in Graves' disease | Q67026280 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Studies on the occurrence of ophthalmopathy in Graves' disease | Q69606497 | ||
| Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study | Q70321449 | ||
| Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts | Q72564662 | ||
| Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate | Q81000990 | ||
| The effect of etanercept on Graves' ophthalmopathy: a pilot study | Q81024281 | ||
| Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy | Q81300166 | ||
| Rituximab in the treatment of thyroid eye disease: science fiction? | Q84746794 | ||
| P433 | issue | 5 | |
| P921 | main subject | immunotherapy | Q1427096 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 385-390 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Current Opinion in Ophthalmology | Q15757956 |
| P1476 | title | The pathophysiology of thyroid eye disease: implications for immunotherapy | |
| P478 | volume | 22 |
| Q26827429 | Acute thyroid eye disease (TED): principles of medical and surgical management |
| Q38232126 | Applications of cell-based bioassays measuring the induced expression of endogenous genes |
| Q49350433 | Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy. |
| Q33844846 | Benzylideneacetophenone derivatives attenuate IFN-γ-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition. |
| Q37010019 | Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy |
| Q33637524 | Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases |
| Q27691806 | Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. |
| Q35843863 | Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy. |
| Q54960708 | Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts. |
| Q90092746 | Etanercept in the treatment of Graves' ophthalmopathy with primary hypothyroidism and rheumatoid arthritis |
| Q58728114 | Frequency of IL-10-producing regulatory B cells associated with disease activity in thyroid-associated orbitopathy |
| Q92638939 | MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves' orbitopathy |
| Q38177287 | Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature |
| Q90179008 | Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor |
| Q38948145 | Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy |
| Q87163836 | Serum prolidase levels in Graves' disease without ophthalmopathy and its association with oxidative status |
| Q97421343 | Teprotumumab: a disease modifying treatment for graves' orbitopathy |
| Q35671939 | Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy |
| Q38795531 | The Aryl Hydrocarbon Receptor and Its Ligands Inhibit Myofibroblast Formation and Activation: Implications for Thyroid Eye Disease |
| Q35915433 | The Effect of (-)-Epigallocatechin-3-Gallate on IL-1β Induced IL-8 Expression in Orbital Fibroblast from Patients with Thyroid-Associated Ophthalmopathy |
| Q36846603 | The protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress |
| Q91789199 | Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm |
| Q38971992 | Thyroid eye disease: a review |
| Q88028387 | Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity |
Search more.